Analysts Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $9.95

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $9.40.

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Friday, March 14th.

Allogene Therapeutics Stock Down 8.6 %

Allogene Therapeutics stock opened at $1.69 on Friday. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.63. The company has a market cap of $354.35 million, a price-to-earnings ratio of -1.08 and a beta of 1.02. The firm’s fifty day moving average is $1.92 and its 200 day moving average is $2.30.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. On average, equities research analysts anticipate that Allogene Therapeutics will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Allogene Therapeutics

In other news, insider Timothy L. Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO David D. Chang sold 46,668 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the sale, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. The trade was a 0.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,866 shares of company stock valued at $194,461 in the last quarter. 24.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Cibc World Markets Corp purchased a new stake in shares of Allogene Therapeutics in the 4th quarter worth $26,000. PAX Financial Group LLC bought a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $27,000. RPO LLC purchased a new stake in Allogene Therapeutics in the fourth quarter worth about $31,000. Caption Management LLC purchased a new stake in Allogene Therapeutics in the fourth quarter worth about $32,000. Finally, Syon Capital LLC bought a new position in Allogene Therapeutics during the 4th quarter worth about $39,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).